BiondVax Pharmaceuticals Ltd. announced that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent. The invention covers the use of BiondVax's universal flu vaccine as a prime-boost to the current commercially available flu vaccine. Results from BiondVax's completed clinical trials have shown significantly increased effectiveness against multiple flu strains.
Market Closed -
Other stock markets
|
Pre-market 07:11:45 am | |||
5.89 USD | +45.07% |
|
5.455 | -7.39% |
Jul. 15 | Sector Update: Health Care Stocks Edge Lower Late Afternoon | MT |
Jul. 15 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Bet on a Trump Win | MT |
1st Jan change | Capi. | |
---|---|---|
-1.07% | 2.73M | |
+22.15% | 46.56B | |
+44.93% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- BVXV Stock
- News Scinai Immunotherapeutics Ltd.
- BiondVax's Universal Flu Vaccine Receives Additional US Patent